The primary purpose of this study is to determine whether the treatment with AZD1981 will affect the pharmacokinetics of pravastatin.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
30
100 mg per oral, twice daily for 8 days
4x100 mg per oral, twice daily for 8 days
40 mg, once daily at Day 1, period A and Day 8, period B
Research Site
Uppsala, Sweden
Pharmacokinetics for pravastatin measured by Cmax and AUC
Pharmacokinetics for pravastatin measured by Cmax and AUC
Time frame: Pharmacokinetic (PK) sampling will be performed on Day 1, period A and on Day 7-8, period B
AUC
Pharmacokinetics for pravastatin measured by AUC\[0-t\],Cmax (tmax), CL/F, t1/2λz, Vz/F, MRT
Time frame: PK sampling will be performed on Day 1, period A and on Day 7-8, period B
AUCτ
Pharmacokinetics for AZD1981 measured by AUCτ,Css,max, Css, max (tmax ss), CLss/F, t1/2λz, Vz/F, MRT
Time frame: PK sampling will be performed on Day 7 and Day 8, period B
Safety and tolerability
Safety and tolerability of AZD1981
Time frame: Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.